JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M200553200 on March 29, 2002

J. Biol. Chem., Vol. 277, Issue 24, 21306-21314, June 14, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/24/21306    most recent
M200553200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balla, Z.
Right arrow Articles by Blasig, I. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balla, Z.
Right arrow Articles by Blasig, I. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Calcium/Calmodulin-dependent Protein Kinase IIdelta 2 and gamma  Isoforms Regulate Potassium Currents of Rat Brain Capillary Endothelial Cells under Hypoxic Conditions*

Zsolt BallaDagger , Brigitte Hoch§, Peter Karczewski§, and Ingolf E. BlasigDagger

From the Dagger  Forschungsinstitut für Molekulare Pharmakologie, Berlin, 13125 Germany and the § Max-Delbrück-Center for Molecular Medicine, Berlin, 13125 Germany

Received for publication, January 18, 2002, and in revised form, March 25, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Endothelial K+ and Ca2+ homeostasis plays an important role in the regulation of tissue supply and metabolism under normal and pathological conditions. However, the exact molecular mechanism of how Ca2+ is involved in the regulation of K+ homeostasis in capillary endothelial cells, especially under oxidative stress, is not clear. To reveal Ca2+-triggered pathways, which modulate K+ homeostasis, Ca2+/calmodulin-dependent protein kinase II and voltage-gated outward K+ currents were studied in rat brain capillary endothelial cells under hypoxia. Whole cell voltage-clamp measurements showed voltage-gated outward K+ current with transient and sustained components. mRNA and protein of Ca2+/calmodulin-dependent protein kinase II delta 2 and two gamma  isoenzymes were identified. Activation of the isoforms (autophosphorylation) was typically achieved by the Ca2+ ionophore ionomycin, which was prevented by the Ca2+/calmodulin-dependent protein kinase II-specific inhibitor KN-93. Hypoxia resulted in autophosphorylation of the delta 2 and gamma B isoforms, augmented the current amplitude, increased the inactivation time constant, and decreased the extent of inactivation of the transient current. KN-93 prevented both the activation of the isoforms and the alterations in the K+ current characteristics. It is concluded that the activation of Ca2+/calmodulin-dependent protein kinase II decreases inactivation of the voltage-gated outward K+ current, thereby counteracting depolarization of the hypoxic endothelium.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Endothelial cells (EC)1 regulate numerous processes of the vasculature, e.g. blood coagulation, angiogenesis, barrier, and transport functions. They serve both as target and release site of vasoactive agents adjusting circulatory parameters (1). As a primary barrier between circulation and tissue, they play a major role in the regulation of fluid and mineral distribution between extravascular and intravascular space. This is effectively controlled by microvascular EC representing a huge surface.

There is an increasing number of ion channel types revealing different expression patterns when comparing EC of different origin (1). They play a role in the regulation of membrane potential (2), Ca2+-signaling pathways (3), cell volume (4), vessel permeability (5), and mechanosensor function (6). Although EC are regarded to be nonexcitable, voltage-gated Ca2+ (7) and K+ (8) channels have been reported. The channels may be involved in the release of vasoactive compounds regulated mainly via intracellular Ca2+ movements. Ion channels are described in a more detailed manner on macrovascular EC. Little is known about microvascular EC. The latter express voltage-dependent Ca2+ (9), Na+ (10), ATP-sensitive (11), and stretch-sensitive nonselective cation (12) channels. Concerning K+ channels, Ca2+-activated (13) and voltage-gated K+ channels (14) have been observed in microvascular EC.

Ionic and the closely related osmotic homeostasis partly regulated by ion channels (K+, Na+, Cl-) play an important role in preserving EC morphology and EC-EC coupling required for normal vessel permeability (15). Morphological impairment of EC, such as swelling or EC disorganization, may cause blood flow disturbances (16) or increased extravasation (17). The tightness of the blood-brain barrier is greatly affected by hypoxia as indicated by increased paraendothelial permeability (18) and endothelial swelling (19). One possible mechanism in endothelial swelling is an alteration of the K+ channel function, which may result in the loss of the K+ recycling pathway necessary for a proper Na+,K+-ATPase function (20).

Members of the diverse superfamily of voltage-activated K+ channels have been demonstrated to be modulated by phosphorylation catalyzed by different protein kinases, among them Ca2+/calmodulin-dependent protein kinase II (CaMKII). Phosphorylation of the K+ channel subtype Kv1.4 at the N terminus by CaMKII affects the fast inactivation kinetics and the current amplitude (21). Modulation of K+ current inactivation by CaMKII is reported in excitable cells such as atrial myocytes (22) and colonic smooth muscle cells (23).

CaMKII is a ubiquitously expressed Ser/Thr protein kinase and transmits Ca2+ signals to a variety of targets ranging from ion channels to transcription factors. CaMKII is encoded by four separate genes (alpha , beta , gamma , delta ) with partial tissue-specific expression of its subunits and their numerous splicing variants (24). In the macrovascular endothelium CaMKII is shown to be involved in the mechanism of thrombin-induced barrier dysfunction (25), and NO synthase regulation (26, 27). As intracellular Ca2+ is increased in EC under pathological conditions, such as hypoxia (28), CaMKII activation is a potential candidate to be involved in the mechanisms of such a cell injury.

Here we hypothesize that CaMKII is activated in EC upon oxidative stress, which in turn modulates K+ channels involved in maintaining the endothelial supply and barrier function. Therefore, the aim was to elucidate the effect of hypoxia on CaMKII activity and K+ current in brain capillary endothelial cells forming the blood-brain barrier. The presence and activation of various CaMKII isoenzymes and distinct voltage-gated K+ current components and their modulation were identified under normal and hypoxic conditions. Both the K+ current and the CaMKII activation were sensitive against CaMKII blocker indicating a regulatory relevance of this pathway for the K+ homeostasis of the microvascular endothelium.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chemicals and Antibodies-- Tetraethylammonium-chloride (TEA) and 4-aminopyridine (4-AP) were from Sigma-Aldrich (Taufkirchen, Germany). Charybdotoxin was from Alomone Labs (Jerusalem, Israel). KN-93 water-soluble, KN-92, and ionomycin were from Calbiochem (Bad Soden, Germany).

To detect CaMKIIdelta , a subclass-specific antibody was used recognizing delta  isoforms containing the C-terminal second variable domain (29). For detection of autophosphorylated CaMKII, an antibody was raised in rabbit against the phosphopeptide MHRQEpTVDC corresponding to the amino acid sequence surrounding the autophosphorylation site Thr287 in CaMKIIdelta . The antibody specific for the gamma -class of CaMKII was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Peroxidase-conjugated anti-rabbit IgG was from Sigma-Aldrich. The anti-goat IgG conjugated with peroxidase was obtained from Dianova (Hamburg, Germany). The enhanced chemiluminescence kit was from Amersham Biosciences. All other reagents were of analytical grade or better.

Cell Culture-- Immortalized rat brain capillary endothelial cell line 4 (rBCEC4) (30) was cultured on 10-mm diameter round glass coverslips (Assistent, Berlin, Germany) covered by rat tail collagen for electrophysiology or in 6-well plates (BD PharMingen) for RT-PCR and immunoblotting. Cells were grown in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose, 10% fetal bovine serum, 1.2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin, 100 µg/ml sodium heparin, 110 µg/ml sodium pyruvate, and 10 µg/ml endothelial cell growth factor (ECGF). Cultures were maintained in a humidified atmosphere with 5% CO2 at 37 °C. Medium was changed each second day. Cells were subcultured weekly from passage 20 to 30. For hypoxia, cells were transferred for 5 h to the Concept Plus Anaerobic Workstation (Ruskinn Technology Ltd., Leeds, UK) containing a gas mixture of 90% N2, 5% CO2, and 5% H2 at 37 °C and 100% humidity (31). For analyzing CaMKII autophosphorylation after hypoxia, cells were subjected to normoxic conditions for 30 min up to the fixation to simulate conditions comparable to those used in the patch-clamp experiments. For pretreatment, KN-93 or KN-92 was added to the medium 30 min before starting hypoxia in a quantity to reach a final concentration of 20 µM.

Electrophysiology-- Patch-clamp recordings were performed in whole cell configuration at room temperature (23 °C). Cells were transferred from the culture medium into extracellular solution flowing through a round coverslip recording chamber with a 150-µl volume (RC-25, Warner Instruments Co., Hamden, CT). Control and test solutions were perfused through the chamber by gravity with an 8-10 ml/h perfusion rate. Clearly separated cells were visually selected for patch-clamp recording. A digital camera was used to take images.

Patch pipettes without filament (PGL150T-7.5, Harvard Apparatus Ltd., UK) were pulled and heat-polished directly before use to a final resistance of 2-4 megohm. They were coated with monocomponent elastomer. The extracellular solution contained (in mM): 135, NaCl; 5, KCl; 2, CaCl2; 2, MgCl2; 10, Glucose; 10, HEPES; 1, NaH2PO4 (pH 7.4, adjusted with NaOH). In solutions containing higher concentrations of TEA and 4-AP, Na+ was reduced to maintain constant osmolarity. The pipette-filling solution contained (in mM): 45, KCl; 100, potassium aspartate; 3, MgCl2; 2, Na2ATP; 10, HEPES; 10, EGTA (pH 7.2, adjusted with KOH).

Whole cell K+ currents were measured by an Axopatch 200A amplifier (Axon Instruments, Inc.). Clampex 8.1 software (Axon Instruments, Inc.) was used for command generation and data acquisition. Currents were digitized at 10 kHz and filtered with low-pass Bessel characteristics at 5 kHz frequency. Total cell capacitance and series resistance were calculated and compensated by adjusting the amplifier's whole cell capacitance and series resistance (0-85%) compensation controls. Only cells with access resistance of <10 megohm were accepted for further investigations. Liquid junction potentials were calculated (-10 to -13 mV), and data were corrected for each experimental condition.

Voltage-gated outward potassium currents were elicited by step commands with 1 s duration from -80 to +80 mV in steps of 10 mV preceded by a 2-s prepulse at -90 mV (Fig. 3, Stimulus). The interstimulus interval was set to 10 s. This stimulus protocol is suitable to elicit the A-type K+ current. The amplitude of the sustained current component (Isus) was determined as the amplitude of the outward current at the end of each trace. The maximal amplitude of the transient outward current (Ito) was calculated by subtracting Isus from the peak outward current (Ipeak). The current amplitudes were normalized to cell capacitance in each cell.

RT-PCR-- Total RNA from cells was isolated with the Invisorb system according to the manufacturer's instructions and from rat brain using a guanidine thiocyanate-based method (32). After isolation, remaining DNA contaminations were digested and RNA was re-extracted (29). RT-PCR was performed as described (33). PCR conditions for amplification of isoforms of the four known CaMKII classes are described as follows: alpha  and beta  classes, 3 min, 94 °C denaturation step, 35 cycles (30 s, 94 °C, 30 s, 50 °C, 30 s, 72 °C) of amplification, 5 min, 72 °C final elongation; gamma -class, 1 min, 95 °C denaturation step, 35 cycles (30 s, 94 °C, 1 min, 55 °C, 1 min, 72 °C) of amplification, 7 min, 72 °C final elongation; and delta -class, 3 min, 94 °C denaturation step, 35 cycles (30 s, 94 °C, 1 min, 55 °C, 1 min, 72 °C) of amplification, 7 min, 72 °C final elongation. Specific primer combinations for single delta  isoforms are given in Ref. 29. Transcript patterns of the other classes (alpha , beta , gamma ) were investigated using primer pairs flanking the variable regions of the corresponding class. Therefore, all expressed variants of these classes should be amplified. The forward and reverse sequences of alpha -class-specific primers containing a flanking EcoRI site were as follows: GCG GAA TTC AAG AAT GAT GGC GTG AAG GAA and GCG GAA TTC ACC CTG GCC TGG TCC TTC AAT (accession no. J02942), for the beta -class GAC AGG AGA CTG TGG AAT GTC TGA AGA and AGT CCC CAT TGT TGA CGG CCT CAA TGA (accession no. M16112), and for the gamma -class GCC AAG AGA CAG TGG AGT GCT TAC GCA and CAG CGG TGC AGC AGG GGC TCC TGA GCA GTG ATA (accession no. J04063). PCR products were analyzed with ethidium bromide-stained 2% agarose gels or 4% native polyacrylamide gels. For sequencing, amplification products were extracted from gels, and standard cycle sequencing reactions were performed commercially by InViTek (Berlin-Buch, Germany).

Preparation of Cell Lysates and Immunoblotting-- Cell cultures were washed with HEPES-buffered Hanks balanced salt solution and incubated for 15 min at 37 °C for stabilization. 250 nM ionomycin was used for activation of CaMKII. For inhibition of CaMKII, cells were preincubated with 20 µM KN-93 for 30 min before the addition of ionomycin. Cells were fixed by the addition of ice-cold trichloroacetic acid to a final concentration of 5% and immediately placed on ice. They were washed twice with ice-cold 2.5% trichloroacetic acid and harvested. The precipitates were centrifuged at 12,000 × g at 4 °C for 10 min. The supernatant was aspirated, and the pellets were dissolved in electrophoresis sample buffer at pH 6.8, neutralized if necessary with 1 M Tris, and heated at 95 °C for 5 min. Electrophoretic separation on 10% SDS-polyacrylamide gels and immunoblotting were performed as described in Ref. 29 with 20 µg of cell protein per lane. The autophosphorylated CaMKII-specific antibody was used in a final concentration of 1 µg/ml. The antibodies obtained from commercial sources were used according to the manufacturer's instructions. Visualization of the immunoreaction was by enhanced chemiluminescence kit and autoradiography on x-ray film. Protein was measured in cell soluble lysates by a modified Lowry method (34).

Data Analysis-- Clampfit 8.1 software (Axon Instruments, Inc.) was used for off-line raw data analysis. Further data processing and analysis was performed by MicrocalTM Origin® software (Microcal Software, Inc.). Two-dimensional area measurement of digital images of cultured cells was made by Scion Image for Windows software (Scion Corp., Frederick, MD). The time constant of the fast inactivation phase (tau fast) of the transient current was calculated by biexponential fitting on the decay phase of the outward current. The extent of inactivation was determined as the contribution of the transient outward current to the total peak current (Ito/Ipeak). Values are presented as mean ± S.E. To reveal the significance of differences, paired or unpaired Student's t tests were used with significance defined as: *, p < 0.05; **, p < 0.01.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Swelling of Hypoxic Cells-- Micrographs (Fig. 1) show the same cultured cells before and after the hypoxia protocol. Arrows indicate the regions of apparent swelling. The surface area of the cells subjected to 5 h of hypoxia showed a significant increase compared with the initial values measured before the initiation of hypoxia protocol, whereas in the case of the control cell group, which was measured after the same period without hypoxia, no significant increase was seen. (See Fig. 1; initial value, 481 ± 23 µm2, n = 29; control value, 510 ± 37 µm2, n = 20; hypoxic value, 617 ± 36 µm2, n = 21, p < 0.05 compared with the initial value.) These results suggest that hypoxia caused a significant increase of the cell volume (swelling).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 1.   Swelling of rat brain capillary endothelial cells after hypoxia. Phase contrast light microscopic digital images (×40). Cells subjected to 5 h of hypoxia displayed significant swelling during reperfusion (see arrows) compared with the initial untreated state. The diagram represents the cell surface area of the initial, control, and hypoxic cell groups. The hypoxic group showed a significant increase of cell surface area in contrast to the control group. Both groups were compared with the initial (preincubation) period. Mean ± S.E. *, p < 0.05 compared with the initial value.

Components of the Voltage-gated Outward Potassium Current and Their Selectivity-- To reveal possible pathways involved in the adaptation to swelling and Ca2+ overload caused by hypoxia of rBCEC4, voltage-gated outward potassium currents were investigated. Two different components of the total outward current were identified, a transient outward component (Ito) with fast activation and rapid inactivation and a sustained component (Isus) that showed no inactivation within the period of stimulus waveform (see "Experimental Procedures").

Different potassium channel blockers were used for pharmacological characterization of the outward current components. 4-AP and TEA showed a dose-dependent inhibitory effect on current amplitudes (Fig. 2, A and B). The inhibition revealed different characteristics as presented by a sigmoidal fit to the plots of normalized current values against the concentration of 4-AP (Fig. 2C) and TEA (Fig. 2D). 4-AP blocked Ito with a half-maximal inhibitory concentration (IC50) of 1.1 ± 0.04 mM. The Hill coefficient was 2.9 ± 0.05 (n = 3). 4-AP inhibition reached a maximal effect at 5 mM, which decreased the current amplitude to 9% compared with control values of +70 mV (Fig. 2C). Similar values for the 4-AP effect were reported earlier in EC (13) and myocytes (35). TEA inhibited Isus with an IC50 value of 2.8 ± 0.5 mM and a Hill coefficient of 1.4 ± 0.3 (n = 3). 10 mM TEA reached maximal blocking effect and reduced Isus to 21% of the control amplitude at +70 mV (Fig. 2D). Comparable values of TEA inhibition were observed in EC (13, 14) and neurons (36). 1 µM charybdotoxin, an inhibitor of Ca2+-activated K+ current, did not influence Ito and Isus significantly (not shown).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   The inhibitory effect of potassium channel blockers on outward K+ current components of rBCEC4. Currents were elicited as shown in Fig. 3, Stimulus panel. The amplitude of the sustained current component (Isus) was determined as the amplitude of the outward current at the end of each trace. The maximal amplitude of the transient current (Ito) was calculated by subtracting Isus from the peak outward current (Ipeak). Current amplitudes were normalized to cell capacitances. Current-voltage curves demonstrate the effect of increasing concentrations of 4-AP on Ito (A) and TEA on Isus (B). Current amplitudes registered at +70 mV were normalized to the control (Icont) current amplitude and plotted against the concentration of 4-AP (C) and TEA (D).

Hypoxia Increased the Amplitude of Voltage-gated Outward Potassium Current Components, and KN-93 Impeded the Effect of Hypoxia-- To focus on Ca2+-triggered pathways, which may modulate K+ homeostasis, one group of cells was pretreated with KN-93 before the hypoxia protocol. Registrations were made under control conditions (Fig. 3A), after hypoxia (Fig. 3B), and after hypoxia preceded by KN-93 application (Fig. 3C). The current-voltage (I-V) relationship of Ito and Isus (Fig. 3, D and E) were calculated in each experimental condition mentioned above. In cells subjected to hypoxia the amplitudes of both Ito and Isus were elevated (Ito at +70 mV, 11.5 ± 2.3 pA/pF, n = 22 in control group versus 15.9 ± 1 pA/pF, n = 16 in hypoxic group, p < 0.05; Isus at +70 mV, 11.4 ± 2.4 pA/pF, n = 23 in control group versus 24.1 ± 4.9 pA/pF, n = 18 in hypoxic group, p < 0.01). In cells pretreated with KN-93 Ito and Isus were in the range of the controls (Ito at +70 mV, 10.7 ± 1.7 pA/pF, n = 16, Isus at +70 mV, 10.3 ± 2.4 pA/pF, n = 17).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   The effect of 5 h of hypoxia on potassium current amplitudes in the presence and absence of 20 µM KN-93 added 30 min before hypoxia in rBCEC4. Recordings were obtained in whole cell configuration. Outward current traces were elicited from a holding potential of -90 mV by voltage steps from -80 to +80 mV in steps of 10 mV with a 1-s duration (Stimulus). The current amplitudes were normalized to cell capacitance in each cell. Registrations were made under control conditions (A), after hypoxia (B), and after hypoxia preceded by KN-93 application (C). D, current-voltage (I-V) relationship of the transient current in control condition (open circle ) (n = 22), after hypoxia () (n = 16), and after hypoxia preceded by KN-93 application (black-square) (n = 16). E, I-V relationship of the sustained current in control condition (open circle ) (n = 23), after hypoxia () (n = 18), and after hypoxia preceded by KN-93 application (black-square) (n = 17). Mean ± S.E. *, p < 0.05, **, p < 0.01 compared with the respective control.

KN-92, the inactive analogue of KN-93, was used by the same application protocol as a negative control to reveal that the effect of KN-93 could be related to CaMKII inhibition and not to a direct modulatory effect on K+ channels. KN-92 did not affect the hypoxia-induced elevation of the amplitude of Ito (at +70 mV, 15.6 ± 1.5 pA/pF, n = 11) and Isus (at +70 mV, 23.7 ± 8.8 pA/pF, n = 11).

Inactivation of Ito Decreases after Hypoxia, and the Effect of Hypoxia Is Prevented by KN-93-- tau fast, the time constant of the fast inactivation phase of Ito (see "Experimental Procedures") showed voltage dependence in the +10 to +80 mV voltage range under all experimental conditions (Fig. 4B). Traces shown in Fig. 4A were recorded at +70 mV holding command (Fig. 4, Stimulus) under control conditions and 5 h after hypoxia alone and preceded by KN-93 administration. tau fast elevated significantly after 5 h of hypoxia indicating the slower inactivation of Ito (control group at +70 mV, 76.7 ± 2.5 ms, n = 21 versus hypoxic group at 89.7 ± 3.2 ms, n = 16, p < 0.01). A previous application of KN-93 prevented the effect of hypoxia on tau fast (at +70 mV, 71.6 ± 2.6 ms, n = 15) (Fig. 4B).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   The effect of 5 h of hypoxia on tau fast and Ito/Ipeak in the presence and absence of 20 µM KN-93 added 30 min before hypoxia in rBCEC4. A, superimposition of original current traces recorded at +70 mV holding command (Stimulus) under control conditions and 5 h after hypoxia alone and with KN-93 pretreatment. B, tau fast, the time constant of the fast inactivation phase of Ito, which was derived by biexponential fitting on the decay phase of the transient outward current, was plotted against holding command values under control conditions (open circle ) (n = 21), after 5 h of hypoxia alone () (n = 16), and with KN-93 pretreatment (black-square) (n = 15). C, the extent of inactivation expressed as the contribution of the transient outward current to the total peak current (Ito/Ipeak) is displayed under the control condition (n = 22), after 5 h of hypoxia alone (n = 16), and preceded by KN-93 treatment (n = 15). Mean ± S.E. *, p < 0.05; **, p < 0.01 compared with the respective control.

The Ito/Ipeak ratio, which describes the extent of inactivation (see "Experimental Procedures"), decreased significantly after hypoxia, pointing to a decreased contribution of Ito to the total current (control group, 0.5 ± 0.04, n = 22 versus hypoxic group, 0.4 ± 0.02, n = 16, p < 0.01). In the group subjected to KN-93 application before hypoxia, the Ito/Ipeak value was in the control range (at +70 mV, 0.51 ± 0.04, n = 15) (Fig. 4C).

Pretreatment of the cells with KN-92 before hypoxia did not impeded the alteration of the tau fast value (at +70 mV, 93.4 ± 4.9 ms, n = 11) and the Ito/Ipeak ratio (at +70 mV, 0.4 ± 0.06, n = 11).

mRNA Expression of CaMKII Isoenzymes in rBCEC4 Cells-- To assess the expression pattern of CaMKII in rBCEC4, we determined the mRNA transcript pattern by RT-PCR and immunoblotting with class- or isoform-specific primer combinations (Fig. 5). The class-specific primers for alpha , beta , and gamma  isoforms of CaMKII were derived from the conserved domains of these classes flanking their variable parts. Therefore, all expressed isoforms of these classes should be detected. For delta -CaMKII, primers specific for individual isoforms of this class were used. Since alpha - and beta -CaMKII are known to be neuronally expressed (37), RNA from rat brain was amplified in parallel as a positive control. As expected, no alpha - and beta -CaMKII-specific signals were obtained in rBCEC4 cells, whereas products of the expected sizes were amplified from the brain RNA fraction (Fig. 5, upper left and upper middle). With the gamma -class-specific combination, two products were detected in rBCEC4-derived preparations that were identified by size or by sequencing as isoforms gamma B and gamma C (38) (Fig. 5, upper right). delta -CaMKII is characterized by the appearance of a second C-terminal variable domain (39). To assess the transcript pattern of CaMKIIdelta in rBCEC4 we concentrated on the non-neuronal members of this subclass (isoforms delta 2, delta 3, delta 4, delta 9) (29). As shown in the lower part of Fig. 5, rBCEC4 expressed only transcripts for isoform delta 2. The very faint band arising in delta 4-specific amplification reactions is not close to the size of the positive control obtained with the delta 4-containing plasmids (530 bp, positive control). Therefore, it was considered to be an artifact of the PCR.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   mRNA expression of CaMKII isoenzymes in rBCEC4 cells. RT-PCR signals after 35 cycles of amplification derived from total RNA preparations of rBCEC4 cells (1) and rat brain (3) with primer combinations specific for CaMKII classes alpha  (upper left), beta  (upper middle), gamma  (upper right), and for individual members of the delta -CaMKII class (lower). As a negative control, RT-PCR of rBCEC4 RNA in the absence of reverse transcriptase was carried out (2). Where indicated, control PCR with plasmids containing the corresponding isoforms was done in parallel (positive control). Sequencing of the corresponding signal revealed the identity of a beta -derived rBCEC4 product as an artifact (unspecific). For alpha -, beta -, and delta -CaMKII 2% agarose gels and for the separation of the gamma -CaMKII products, a 4% native polyacrylamide gel were used. Base pair (bp) values represent the bands of the respective standard samples. Arrows indicate the size (bp) of the detected signal.

Protein Expression of CaMKII in rBCEC4-- To analyze the expressed proteins of CaMKII in rBCEC4 based on the mRNA data, CaMKIIdelta - and CaMKIIgamma -specific antibodies were employed. The delta -specific antibody specifically recognizes isoforms with the unique C-terminal extension that comprises a subset of the CaMKIIdelta isoforms known at present (29). The gamma -specific antibody is directed against an amino acid sequence conserved in all known gamma  isoforms, and thus is able to detect all forms of CaMKIIgamma . Fig. 6A shows immunoblots with extracts of rBCEC4. The delta -specific antibody exclusively detects a signal at about 54 kDa (lane 1). Based on our transcript data and the apparent molecular mass, this protein may be attributed to the CaMKII isoform delta 2. The gamma -specific antibody produces three reactive bands at about 60, 54, and 42 kDa. The prominent protein band at 60 kDa correlates with the deduced molecular mass of CaMKIIgamma B, and according to our mRNA data it most likely represents the isoform gamma B. The very faint 54-kDa band, migrating exactly at the position of delta 2, coincides in size with the deduced molecular mass of isoform gamma C. However, we cannot exclude the possibility that the signal is produced by a cross-reaction of the antibody with CaMKIIdelta 2. The nature of the prominent immunoreactive protein band at about 42 kDa remains to be identified. It is not in the size range of any known CaMKII protein.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Protein expression and activation of CaMKII isoenzymes in rBCEC4. A, expression of CaMKII protein. Lane 1 shows the immunoreactivity obtained with the CaMKIIdelta -specific antibody, lane 2 gives the reaction with the CaMKIIgamma -specific antibody. B, autophosphorylation of CaMKIIgamma and delta  isoforms in rBCEC4 by the addition of ionomycin without and after 30 min of preincubation with KN-93 (20 µM). c, control: iono, ionomycin (250 nM). The arrows indicate the positions of approximately 54 kDa for CaMKIIdelta and 60 kDa for CaMKIIgamma obtained with the antibody directed against the autophosphorylated forms of CaMKII. MM is molecular mass.

Activation of CaMKII Isoforms in rBCEC4-- CaMKIIdelta 2 and CaMKIIgamma became autophosphorylated when rBCEC4 were subjected to ionomycin. At a concentration of 250 nM ionomycin leads to the detection of two protein bands by the CaMKII autophosphorylation site-specific antibodies, corresponding to the positions of CaMKIIdelta 2 (54 kDa) and CaMKIIgamma B (60 kDa). The autophosphorylation of the 54-kDa protein was very low in controls and increased quickly and transiently in response to ionomycin with the maximum of 30 s. It was not detectable anymore at 10 min. In contrast, the 60-kDa protein showed an apparent higher basal level of autophosphorylation that increased more slowly after ionomycin application and remained stable for at least 10 min. Interestingly, there was no autophosphorylation-specific reaction at the position of 42 kDa, supporting our assumption that the protein detected by anti-CaMKIIgamma does not represent a functional CaMKII isoform. A 30-min pretreatment with 20 µM KN-93 reduced the autophosphorylation of both isoenzymes considerably (Fig. 6B).

Effect of Hypoxia on CaMKII Autophosphorylation in rBCEC4-- Hypoxia resulted in activation of CaMKII in rBCEC4 as demonstrated by autophosphorylation of both CaMKIIdelta 2 and CaMKIIgamma (Fig. 7A). In controls there was only very low autophosphorylation detectable for delta 2, which increased significantly because of hypoxia (control, 10 ± 2.6 OD, n = 3 versus hypoxia, 85.6 ± 7.4 OD, n = 5, p < 0.01) (Fig. 7B). In control cells gamma B elicits a higher autophosphorylation than delta 2 resulting in hypoxia-treated cells in a higher maximum. However, the cells show a smaller increment of autophosphorylation compared with that of delta 2. The increase in autophosphorylation of the gamma B isoenzymes was about 60% and statistically significant (control, 74.3 ± 5.7 OD, n = 3 versus hypoxia, 121.8 ± 10.7 OD, n = 5, p < 0.05). The CaMKII inhibitor KN-93 completely abolished the response in autophosphorylation to hypoxia for both CaMKIIdelta 2 (11.6 ± 1.6 OD, n = 5) and CaMKIIgamma (75.6 ± 9.9 OD, n = 5).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of 5 h of hypoxia of rBCEC4 on autophosphorylation of CaMKII isoenzymes in the absence and presence of KN-93. Control cultures (sample 1), hypoxic cultivated cells (sample 2), and hypoxic cultivated cells in the presence of 20 µM KN-93 (sample 3). A, immunoblot with the respective autophosphorylation site-specific antibodies (P-CaMKIIgamma , P-CaMKIIdelta ). B, quantification of optical density of the immunoblots in 3-5 individual culture dishes of each experimental group. MM is molecular mass. Mean ± S.E. *, p < 0.05; **, p < 0.01, compared with the respective control.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The current study for the first time provides evidence for a role of CaMKII in the regulation of voltage-gated K+ channels in hypoxic rat brain capillary endothelial cells. A function of the CaMKII has been described in macrovascular endothelial cells but not in the widely differentiated microvasculature that is specialized depending on surrounding tissue. In aortic endothelial cells, CaMKII can be involved in the response to oxidative stress caused by H2O2 (26) or in thrombin-induced cytoskeletal reorganization and endothelial barrier dysfunction (25). The isoenzyme pattern of CaMKII in the endothelium is unknown. In this study the presence of CaMKIIdelta 2 and CaMKIIgamma is demonstrated in brain capillary endothelial cells, and evidence is presented for their functional coupling to voltage-gated K+ currents under hypoxic conditions. Hypoxia increases the intraendothelial free Ca2+ concentration as shown earlier (28). The isoenzymes identified in rBCEC4 are activated (autophosphorylated) in a Ca2+-dependent manner by hypoxia. The autophosphorylation and the alteration of the K+ current characteristics, both caused by hypoxia, are prevented by the selective CaMKII inhibitor KN-93.

The function of the outward voltage-gated K+ current measured in the brain capillary endothelial cells used in the current study is probably related to the regulation of membrane potential. K+ channels are involved in membrane potential regulation in depolarized cells, and they can counteract further membrane depolarization (14). This may possess a regulatory function during membrane potential oscillations elicited by vasoactive agonists (40) or during membrane depolarization caused by oxidative stress (41). Regulation of membrane potential plays a pivotal role in Ca2+ homeostasis since voltage-gated Ca2+ channels serve as one possible pathway for Ca2+ influx (42).

In rBCEC4 we found a transient and a sustained K+ current component. The characteristics of the transient current corresponds to the A-type, a fast-activating and fast-inactivating outward voltage-gated K+ current. To the sustained component, a delayed rectifier current contributes to a great extent as demonstrated by the effect of TEA. Both the A-type and the delayed rectifier current are reported to be present in primary capillary endothelial cells (13, 14). This means that rBCEC4 preserves primary properties, making them suitable for further electrophysiological studies. Moreover, the action of the specific K+ channel blockers 4-AP and TEA suggests that the majority of the outward current is carried by K+. Finally, the absence of a charybdotoxin effect indicates that Ca2+-activated K+ channels are not directly involved in the modulation of the voltage-gated K+ current components investigated.

Upon hypoxia, rBCEC4 shows an increased tau  value and a reduced Ito/Ipeak ratio, indicating a decrease of the transient current inactivation that leads to elevation of the transient and sustained K+ current components. A similar change in K+ currents has been observed in myocytes dialyzed with autophosphorylated CaMKII (23). The hypoxia-related rise in the tau  value, the diminished Ito/Ipeak ratio, and the elevated transient and sustained K+ current amplitudes can be prevented by the specific CaMKII inhibitor KN-93. Taken together, the assumption is supported that CaMKII enhances the release of K+ from hypoxic rBCEC4 when voltage-gated K+ channels are operating.

Immunohistochemistry experiments reveal an expression of Kv1.4 channels in rBCEC4 (data not shown). These channels are rapidly inactivated via their N-terminal inactivation domain (43). In human embryonic kidney (HEK) cells, phosphorylation of the N-terminal part of the transfected Kv1.4 channel by CaMKII decelerates the inactivation of the fast-inactivating A-type current (21). Therefore, it is proposed that CaMKII regulates the inactivation of the K+ current in rBCEC4. This conclusion is supported by a considerable deceleration of the transient current inactivation under hypoxic conditions when the detected CaMKII isoenzymes were activated. It is known that voltage-gated K+ channels can be modulated by serine/threonine phosphorylation regulated by Ca2+ (44). CaMKII is such a Ca2+-dependent serine/threonine protein kinase (24). The assumption of a CaMKII-regulated K+ current is further supported by using the CaMKII inhibitor KN-93, which inhibits the activation of CaMKII and prevents the decrease of the inactivation of the K+ current in our experiments. Up to now, CaMKII-regulated K+ channels have not been reported in nonexcitable cells. In myocytes the regulation of a transient A-type K+ current by CaMKII is described under control conditions that are sensitive to KN-93 (22, 23). To our knowledge, a function of CaMKII has not yet been known for disturbances caused by oxidative stress.

Beside its specific CaMKII inhibitory effect, KN-93 can exert a nonspecific action on K+ currents directly blocking K+ channels. In rabbit smooth muscle cells KN-93 blocks the voltage-dependent K+ current significantly and dose dependently in a manner that is similar to its non-CaMKII inhibiting analogue KN-92 (45). In our experiments the action of KN-93 was specific; its effect was confined to CaMKII inhibition only. This is confirmed since KN-92 has no effect on tau  and Ito/Ipeak value or the current amplitudes under hypoxic conditions.

After hypoxia we have found a significant cell swelling that is a typical sign of hypoxic cell injury (19). Activation of the CaMKII isoenzymes observed in parallel reflects enhanced intracellular Ca2+ concentration. The hypoxic increase of cytosolic Ca2+ and the hypoxic cell swelling are well described in endothelial cells (28). Hypoxia experiments on cultured human endothelial cells give evidence that the Ca2+ uptake is mainly due to the influx of extracellular Ca2+ (46). Cellular Ca2+ accumulation is known to be related to morphological changes. Laser scanning microscopic studies revealed that bleb formation induced by hypoxic stress involves regional elevation of Ca2+ in human umbilical vein endothelial cells (47). In addition, hypoxia impairs the blood-brain barrier function of brain endothelial cells as indicated by increased paraendothelial permeability (18). In our investigation hypoxia conditions (18, 28) that are proven to elevate the cytosolic concentration of Ca2+ (28) necessary to intensify the activation of CaMKII were used.

As we show here for the first time, brain capillary endothelial cells express non-neuronal members of the CaMKIIgamma and CaMKIIdelta classes at both the transcript and protein levels. There are no transcripts of the primarily neuronally expressed alpha  and beta  subunits of CaMKII (24) that are detectable. From the known CaMKIIdelta isoenzymes being prominently expressed in non-neuronal excitable tissue, only delta 2 is detected in rBCEC4. delta 2 is ubiquitously expressed in cells of peripheral tissues and represents a constitutively expressed isoform in the heart (29, 48, 49). Transcripts of two isoenzymes of CaMKIIgamma are identified in rBCEC4. Immunoblot experiments give evidence that gamma B protein is expressed, whereas a faint band is consistent in size with the predicted molecular mass of gamma C but may also result from a cross-reaction with the highly expressed delta 2 protein. gamma B has been demonstrated to elicit higher total as well as autonomous autophosphorylation-dependent catalytic activity than gamma C (50). Thus, our data suggest that gamma B is the dominant isoform of the CaMKIIgamma class in brain capillary endothelial cells.

In response to the elevation of intracellular Ca2+ by treatment with ionomycin, as demonstrated in rBCEC4, delta 2 shows a more rapid activation in terms of autophosphorylation compared with CaMKII gamma B. Autophosphorylation of gamma B in response to ionomycin occurs more slowly but remains at plateau levels, whereas delta 2 is rapidly dephosphorylated. This different time course of activation can be due to differences in the accessibility of activating Ca2+ and/or calmodulin, e.g. by distinct intracellular localization of the isoenzymes, different phosphatase action, or specific properties of individual CaMKII isoforms. It has been shown that gamma B needs higher concentrations of calmodulin for activation, but gamma B binds calmodulin more tightly than other CaMKIIgamma isoforms (51). However, kinetic properties of members of the CaMKIIdelta class have not yet been investigated. After hypoxic treatment of rBCEC4 autophosphorylation of both delta 2 and gamma B is found to be significantly elevated. The response to hypoxia appears to be more pronounced for delta 2. Previous findings on a rat myoblast cell line show that delta 2 also localizes to the plasma membrane (29). This supports the notion that delta 2 may be involved in the modulation of K+ channel properties in rBCEC. The autophosphorylation of CaMKII persisted after hypoxia for a longer time. Thus, CaMKII remains activated during measurement of the K+ current, and it is most likely that the hypoxia-induced changes of K+ channel properties are caused by CaMKII activation.

In conclusion, one can state that because of hypoxic ATP reduction (19), elevation of cytoplasmic Ca2+ level (28) results in the activation of CaMKIIdelta 2, which is thought to be mainly responsible for decreasing the inactivation of the outward K+ current. Our results concerning the increased outward K+ current mediated by the activation of CaMKII support the hypothesis that this pathway may augment the counteracting regulatory effect against depolarization caused by hypoxia.

Acknowledgments-- We thank Barbara Eilemann for cultivation of the cells and Dorothea Riege and Ingrid Ameln for expert technical assistance.

    FOOTNOTES

* This work was supported in part by Grants Sonderforschungsbereich 507 TP A2, Deutsche Forschungsgemeinschaft GK 238-2, BL 308/6-1, Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie BEO 0311466C (to I. B.), and Kra 1330/3-2 from the Deutsche Forschungsgemeinshaft (to P. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germany. Tel.: 49 30 94793-244; Fax: 49 30 94793-243; E-mail: iblasig@fmp-berlin.de.

Published, JBC Papers in Press, March 29, 2002, DOI 10.1074/jbc.M200553200

    ABBREVIATIONS

The abbreviations used are: EC, endothelial cells; CaMKII, Ca2+/calmodulin-dependent protein kinase II; rBCEC4, rat brain capillary endothelial cell line 4; TEA, tetraethylammonium chloride; 4-AP, 4-aminopyridine; Ito, transient outward current; Isus, sustained outward current; Ipeak, peak outward current; RT-PCR, reverse transcriptase-PCR.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Nilius, B., Viana, F., and Droogmans, G. (1997) Annu. Rev. Physiol. 59, 145-170[CrossRef][Medline] [Order article via Infotrieve]
2. Daut, J., Standen, N. B., and Nelson, M. T. (1994) J. Cardiovasc. Electrophysiol. 5, 154-181[Medline] [Order article via Infotrieve]
3. Busse, R., Mulsch, A., Fleming, I., and Hecker, M. (1993) Circulation 87, 18-25
4. Nilius, B., Oike, M., Zahradnik, I., and Droogmans, G. (1994) J. Gen. Physiol. 103, 787-805[Abstract/Free Full Text]
5. He, P., and Curry, F. E. (1991) Am. J. Physiol. 261, H1246-1254[Medline] [Order article via Infotrieve]
6. Lansman, J. B., Hallam, T. J., and Rink, T. J. (1987) Nature 325, 811-813[CrossRef][Medline] [Order article via Infotrieve]
7. Bkaily, G., d'Orleans-Juste, P., Naik, R., Perodin, J., Stankova, J., Abdulnour, E., and Rola-Pleszczynski, M. (1993) Br. J. Pharmacol. 110, 519-520[Medline] [Order article via Infotrieve]
8. Takeda, K., Schini, V., and Stoeckel, H. (1987) Eur. J. Physiol. (Pfluegers Arch.) 410, 385-393
9. Bossu, J. L., Elhamdani, A., and Feltz, A. (1992) FEBS Lett. 299, 239-242[CrossRef][Medline] [Order article via Infotrieve]
10. Walsh, K. B., Wolf, M. B., and Fan, J. (1998) Am. J. Physiol. 274, H506-512[Medline] [Order article via Infotrieve]
11. Popp, R., and Gogelein, H. (1992) Biochim. Biophys. Acta 1108, 59-66[Medline] [Order article via Infotrieve]
12. Popp, R., Hoyer, J., Meyer, J., Galla, H. J., and Gogelein, H. (1992) J. Physiol. 454435-454449
13. Jow, F., Sullivan, K., Sokol, P., and Numann, R. (1999) J. Membr. Biol. 167, 53-64[CrossRef][Medline] [Order article via Infotrieve]
14. Dittrich, M., and Daut, J. (1999) J. Physiol. 277, H119-127
15. Dejana, E., Corada, M., and Lampugnani, M. G. (1995) FASEB J. 9, 910-918[Abstract]
16. Mazzoni, M. C., Borgstrom, P., Warnke, K. C., Skalak, T. C., Intaglietta, M., and Arfors, K. E. (1995) Int. J. Microcirc. Clin. Exp. 15, 265-270[Medline] [Order article via Infotrieve]
17. Ward, B. J., and Firth, J. A. (1989) J. Mol. Cell. Cardiol. 12, 1337-1347
18. Giese, H., Mertsch, K., and Blasig, I. E. (1995) Neurosci. Lett. 191, 169-172[CrossRef][Medline] [Order article via Infotrieve]
19. Mertsch, K., Grune, T., Siems, W. G., Ladhoff, A., Saupe, N., and Blasig, I. E. (1995) Cell. Mol. Biol. Res. 41, 243-253
20. Watsky, M. A., Cooper, K., and Rae, J. L. (1992) J. Membr. Biol. 128, 123-132[Medline] [Order article via Infotrieve]
21. Roeper, R., Lorra, C., and Pongs, O. (1997) J. Neurosci. 17, 3379-3391[Abstract/Free Full Text]
22. Tessier, S., Karczewski, P., Krause, E-G., Pansard, Y., Acar, C., Lang-Lazdunski, M., Mercadier, J-J., and Hatem, S. N. (1999) Circ. Res. 85, 810-819[Abstract/Free Full Text]
23. Koh, S. D., Perrino, B. A., Hatton, W. J., Kenyon, J. L., and Sanders, K. M. (1999) J. Physiol. (Lond.) 517, 75-84[Abstract/Free Full Text]
24. Braun, A., and Schulman, H. (1995) Annu. Rev. Physiol. 57, 417-445[CrossRef][Medline] [Order article via Infotrieve]
25. Borbiev, T., Verin, A. D., Shi, S., Liu, F., and Garcia, J. G. N. (2001) Am. J. Physiol. 280, L983-990
26. Cai, H., Davis, M. E., Drummond, G. R., and Harrison, D. G. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 1571-1576[Abstract/Free Full Text]
27. Flemming, I., Fisslthaler, B., Dimmeler, S., Kemp, B. E., and Busse, R. (2001) Circ. Res. 88, E68-75[CrossRef][Medline] [Order article via Infotrieve]
28. Mertsch, K., Grune, T., Kunstmann, S., Wiesner, B., Ladhoff, A. M., Siems, W. G., Haseloff, R. F., and Blasig, I. E. (1998) Biochem. Pharmacol. 56, 945-954[CrossRef][Medline] [Order article via Infotrieve]
29. Hoch, B., Haase, H., Schulze, W., Hagemann, D., Morano, I., Krause, E. G., and Karczewski, P. (1998) J. Cell. Biochem. 68, 259-268[CrossRef][Medline] [Order article via Infotrieve]
30. Blasig, I. E., Giese, H., Schroeter, M. L., Sporbert, A., Utepbergenov, D. I., Buchwalow, I. B., Neubert, K., Schönfelder, G., Freyer, D., Schimke, I., Siems, W-E., Paul, M., Haseloff, R. F., and Blasig, R. (2001) Microvasc. Res. 62, 114-127[CrossRef][Medline] [Order article via Infotrieve]
31. Schroeter, M. L., Müller, S., Lindenau, J., Wiesner, B., Hanisch, U. K., Wolf, G., and Blasig, I. E. (2001) Neuroreport 12, 2513-2517[CrossRef][Medline] [Order article via Infotrieve]
32. Kingston, R. E., Chomczynski, P., and Sacchi, N. (1994) in Curr. Protocols in Mol. Biol. (Ausubee, F. M. , Brent, R. , Kingston, R. E. , Moore, D. D. , Seidman, J. G. , Smith, d. A. , and Struhl, K., eds), Vol. 1 , pp. 4.2.1-4.2.7, John Wiley & Sons, New York
33. Hoch, B., Wobus, A. M., Krause, E. G., and Karczewski, P. (2000) J. Cell. Biochem. 79, 293-300[CrossRef][Medline] [Order article via Infotrieve]
34. Lowry, O. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
35. Uese, K., Hagiwara, N., Miyawaki, T., and Kasanuki, H. (1999) J. Mol. Cell. Cardiol. 31, 1975-1984[CrossRef][Medline] [Order article via Infotrieve]
36. Wang, H-S., Pan, Z., Shi, W., Brown, B. S., Wymore, R. S., Cohen, I. S., Dixon, J. E., and McKinnon, D. (1998) Science 282, 1890-1893[Abstract/Free Full Text]
37. Tobimatsu, T., and Fujisawa, H. (1989) J. Biol. Chem. 264, 17907-17912[Abstract/Free Full Text]
38. Nghiem, P., Saati, S. M., Martens, C. L., Gardner, P., and Schulman, H. (1993) J. Biol. Chem. 268, 5471-5479[Abstract/Free Full Text]
39. Mayer, P., Möhling, M, Idlibe, D., and Pfeiffer, A. (1995) Basic Res. Cardiol. 90, 372-379[CrossRef][Medline] [Order article via Infotrieve]
40. Langheinrich, U., Mederos Schnitzler, M., and Daut, J. (1998) Eur. J. Physiol. (Pfluegers Arch.) 435, 435-438
41. Jovanovic, S., and Jovanovic, A. (2001) Int. J. Mol. Med. 7, 639-643[Medline] [Order article via Infotrieve]
42. Cannell, M. B., and Sage, S. O. (1989) J. Physiol. (Lond.) 419, 555-568[Abstract/Free Full Text]
43. Hoshi, T., Zagotta, W. N., and Aldrich, R. W. (1991) Neuron 7, 547-556[CrossRef][Medline] [Order article via Infotrieve]
44. Schulman, H. (1995) Curr. Opin. Neurobiol. 5, 375-381[CrossRef][Medline] [Order article via Infotrieve]
45. Ledoux, J., Chartier, D., and Leblanc, N. (1998) J. Pharmacol. Exp. Ther. 290, 1165-1174
46. Arnould, T., Michiels, C., Alexandre, I., and Remacle, J. (1992) J. Cell. Physiol. 152, 215-221[CrossRef][Medline] [Order article via Infotrieve]
47. Ikeda, M., Ariyoshi, H., Sakon, M., Kambayashi, J., Yoshikawa, N., Shinoki, N., Kawasaki, T., and Monden, M. (1998) Cell Calcium 24, 49-57[CrossRef][Medline] [Order article via Infotrieve]
48. Srinavasan, M., Edamn, C. F., and Schulman, H. (1994) J. Cell Biol. 126, 839-852[Abstract/Free Full Text]
49. Hagemann, D., Hoch, B., Krause, E. G., and Karczewski, P. (1999) J. Cell. Biochem. 74, 202-210[CrossRef][Medline] [Order article via Infotrieve]
50. Singer, H. A., Benscoter, H. A., and Schworer, C. M. (1997) J. Biol. Chem. 272, 9393-9400[Abstract/Free Full Text]
51.